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Abstract
Immunotherapy treatments for cancer are becoming increasingly successful, however to
further improve our understanding of the T-cell recognition involved in effective responses
and to encourage moves towards the development of personalised treatments for leukae-
mia immunotherapy, precise antigenic targets in individual patients have been identified.
Cellular arrays using peptide-MHC (pMHC) tetramers allow the simultaneous detection of
different antigen specific T-cell populations naturally circulating in patients and normal
donors. We have developed the pMHC array to detect CD8+ T-cell populations in leukaemia
patients that recognise epitopes within viral antigens (cytomegalovirus (CMV) and influenza
(Flu)) and leukaemia antigens (including Per Arnt Sim domain 1 (PASD1), MelanA, Wilms’
Tumour (WT1) and tyrosinase). We show that the pMHC array is at least as sensitive as
flow cytometry and has the potential to rapidly identify more than 40 specific T-cell popula-
tions in a small sample of T-cells (0.8–1.4 x 106). Fourteen of the twenty-six acute myeloid
leukaemia (AML) patients analysed had T cells that recognised tumour antigen epitopes,
and eight of these recognised PASD1 epitopes. Other tumour epitopes recognised were
MelanA (n = 3), tyrosinase (n = 3) and WT1126-134 (n = 1). One of the seven acute lympho-
cytic leukaemia (ALL) patients analysed had T cells that recognised the MUC1950-958 epi-
tope. In the future the pMHC array may be used provide point of care T-cell analyses,
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Introduction
The outcomes for patients with leukaemia have improved considerably over the last 30 years
due to enhancements in supportive care, expertise and the development of haematopietic stem
cell transplants. Most patients now achieve a first remission following combinational chemo-
therapy protocols, but the best treatment option for patients for whom it is applicable remains
allo-transplantion, an option which depends on meeting health criteria and donor availability.
First remission is expected to be the optimal time-point for immunotherapy to be adminis-
tered, when residual disease loads are low.
Tumour antigens have been shown to induce specific T-cell responses in patients and thus
act as targets for immunotherapy treatments [1–3]. A number of end-point assays have been
developed to assess both cellular (Enzyme-Linked ImmunoSpo (ELISpot), cytotoxic T-lym-
phocyte (CTL) assays) and humoral (enzyme-linked immunosorbent assay (ELISA)) immune
responses induced in patients during immunotherapy clinical trials, for use as indicators of
clinical efficacy. The development of peptide–MHC tetramers (pMHC) [4] and variants
thereof [5,6] have allowed the visualization of antigen-specific T cells through flow cytometry
and the use of in situ [7] approaches. Such analyses have enabled specific T-cell enumeration,
assessment of cytokine production/secretion (flow based assays, ELIspot) and the expansion of
T-cell populations for functional analysis (CTL analysis). However flow cytometry is techni-
cally difficult, time consuming, expensive and, until recently, limited to only one or a very few
antigen specificities per sample [8]. This changed with the description of pMHC microarrays
by Soen et al in 2003 [9]. Soen et al demonstrated the potential of the pMHC arrays to detect
OVA-antigen specific populations from both T-cell receptor (TCR) transgenic and wild type
mice. Subsequently Chen et al [10] used the pMHC arrays to detect multiple T-cell populations
in 11 human leukocyte antigen (HLA)-A0201 positive patients with resected stage IIC/III and
IV melanoma who were undergoing a melanoma-associated peptide vaccine trial. In addition
to showing the presence of specific T-cell populations that could recognise epitopes within
independent antigens, the authors demonstrated functionality through the co-spotting of
pMHCs with a panel of cytokines.
Similar methods such as the Fluorescence-activated cell sorting (FACS)-based “combinato-
rial encoding” approach [8,11], despite being elegant and robust, are limited in the number of
T-cell populations they can detect (25 and15 different T-cell populations in a single sample,
respectively). Hadrup et al [8] suggested that the analysis of more than 100 T-cell populations
per sample may be possible in the future through the use of a larger number of fluorochromes
and multi-dimensional combinatorial encoding while Newell et al [11] stated that 31 and 63
populations could be analysed with five- and six-colour FACs. Recently Newell et al [12] dem-
onstrated that through combining combinatorial [8,11] and mass cytometry–based pMHC
staining approaches [13] that they could detect more than 100 specific T-cell populations as
well as 20–30 phenotypic markers, in a single blood or intestinal lymphocyte sample. However
combinatorial approaches require expensive reagents (quantum dots [8]) and/or complex mul-
tifactorial analysis, with four or more multi-laser FACS analysis being essential.
We have developed a pMHC array to analyse T cells from leukaemia patients to determine
epitope-specific recognition from a range of cancer-testis (CT) and leukaemia-associated
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antigens (LAAs). In contrast with previous studies, these samples were taken either at disease
presentation prior to treatment or at relapse following conventional therapies and none of the
samples were stimulated to expand specific T-cell populations prior to pMHC array analysis.
Materials and Methods
Patient samples
All research involving human participants was approved by the National Research Ethics Com-
mittee South Central (REC Reference 07/H0606/88), and all clinical investigation were con-
ducted according to the principles expressed in the Declaration of Helsinki. Written informed
consent was obtained from every participant. Normal donor buffy coats were obtained from
the National Blood Service UK or patient samples (26 AML, five chronic myeloid leukaemia
(CML) and seven ALL)(S1 Table) and healthy donor blood were obtained from the Depart-
ment of Haematology, Southampton General Hospital following informed consent (Local
Research Ethics Committee, Southampton University Hospitals NHS Trust, Southampton U.
K., LREC submission number 228/02/T). Red blood cells were lysed using red cell lysis buffer
(15.5mM ammonium chloride (NH4Cl), 1mM potassium bicarbonate, 0.01mM EDTA pH8.0).
If dead cells exceeded 40% of the total cell number then they were positively removed using the
Miltenyi dead cell removal kit and CD8+ T cells were negatively isolated from using EasySep
CD8 T-Cell Enrichment kit (containing beads to deplete CD4, CD14, CD16, CD19, CD20,
CD36, CD56, CD123, GlyA, T cell receptor (TCR)-gd) with CD11b Depletion (EasySep) to
consistently provide97% purity of “untouched” CD8+ T cells as determined by flow cytome-
try. All cells which were not used immediately were stored in EX-VIVO 15TM at a final cell
number of 107cells/ml (BioWhittackerTM, Cambrex,) in the presence of 1% human AB sera
and 10% DMSO (both Sigma). CMV serology was determined by standard techniques.
pMHCmolecules
Peptides for MHCmultimers and functional assays were synthesised using standard Fmoc
chemistry ([4];http://www.syfpeithi.de/) and used as described previously [14]. Biotinylated
recombinant MHC peptide monomers, using peptides with well-documented MHC binding
on www.syfpeithi.de, were produced essentially as described previously [15]. Briefly, fluores-
cent multimers were freshly generated by co-incubating biotinylated HLA peptide monomers
with 95% streptavidin: 5% streptavidin-AF532 (Molecular Probes, Leiden, the Netherlands) for
the pMHC arrays and streptavidin-phycoerythrin (SA-PE) for flow cytometry at a 4:1 molar
ratio.
pMHC arrays
Hydrogel slides were prepared in-house as described previously [16]. pMHC tetramers
(Table 1) were spotted onto hydrogel slides using a contact deposition-type QArray2 printer
and HPLF 0.3mm solid tip pins (Genetix), at a concentration of 0.5mg/ml in PBS and 2% glyc-
erol. Approximately 1ng of pMHC tetramer was spotted at each touch point on the hydrogel.
Printed arrays were immobilised at 4°C in enhanced humidity (75%) achieved through the co-
incubation of slides with wet NaCl in sectioned sealed boxes, for 48 hours. Excess moisture was
removed from the non-gel surfaces of the slides and the arrays stored in a sealed box at 4°C
prior to use. The selected array was warmed to room temperature. 106/ml CD8+ T cells were
labelled using a DiD lipophilic tracer (Molecular Probes) according to manufacturer’s instruc-
tions and the cells washed three times in colourless X-VIVO 15 (BioWhittacker). Cells were
resuspended at 2.5 x 106/ml in colourless X-VIVO 15 and 400μl incubated for 20min at 37°C
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with the pMHC array (Fig 1). Unbound cells were removed by aggressive flicking of the slide,
followed by two washes with 10ml warm colourless X-VIVO 15. Excess culture medium was
removed before slides were analysed on the ProScanArray (PerkinElmer). Negative controls of
AF532 in printing media and random library tetramers [17] were also included. All pMHC
spots were printed in blocks of 3 x 3 or 6 spots as part of 1 or 2 consecutive rows and the whole
pMHC array of spots was repeated at two independent sites on each hydrogel slide. Hydrogel
slides were analysed after incubation with patient samples in the ProScanAarray (Perkin
Elmer) to detect binding of labelled T cells to spotted pMHCs.
Optimisation of the pMHC array
Cut-off points for scoring were decided following the analysis of normal donor CD8+ cells on
the pMHC array during the optimisation phase. Although we could look at each spot on the
array at high magnification and see individual T cells sticking to spots, we found that when 40
or more cells were bound to a spot we could score this reproducibly as positive at X100 magni-
fication, and when it occurred on three of six spots in two independent regions of the array it
concurred with pMHC staining of specific T cells in flow cytometry and CMV-serology data.
We reduced background on the pMHC array through aggressive washing and, although back-
ground varied somewhat between patient samples, it was easily visualised by virtue of the non-
specific sticking of cells and debris outside the area of each pMHC spot. These “dirty” samples
Table 1. pMHCs used on the array to detect virus and LAA-specific T cell populations within the peripheral blood CD8+ population of leukaemia
patients.
Epitope HLA type Amino acid sequence Refa Epitope HLA type Amino acid sequence Refa
ALK-SLA human HLA-A*0201 SLAMLDLLHV [18] p68 RNA-helicase HLA-A*0201 YLLPAIVHI [19]
CMV pp65 HLA-A*0201 NLVPMVATV [20] Survivin5-11 HLA-A*0201 TLPPAWQPL [21]
Flu M1 HLA-A*0201 GILGFVFTL [22] Survivin96-104 HLA-A*0201 LTTLGEFLKL [21]
G250 HLA-A*0201 HLSTAFARV [23] Tyrosinase HLA-A*0201 YMDGTMSQV [24]
Gp100 HLA-A*0201 KTWGQYWQV [25] VMSA_HPBV HLA-A*0201 WLSLLVPFV [26]
HAGE HLA-A*0201 DLILGNISV [27] WT137-45 HLA-A*0201 VLDFAPPGA [28]
HBV HLA-A*0201 FLLTRILTI [29] WT1126-134 HLA-A*0201 RMFPNAPYL [30]
HPV16 E7 HLA-A*0201 YMLDLQPETT [31] EBV_BMRF1105-114 HLA-A*0101 mut AVEQASLQFY NK
HPV16 L1 HLA-A*0201 ICWGNQLFV [5] EBV_BZLF340-348 HLA-A*0101 mut VVETLSSSY NK
Library HLA-A*0201 c [17] EBV BZLF HLA-A*0101 245Vb DSELEIKRY NK
MelanA mod HLA-A*0201 ELAGIGILTV [32] LMP2_EBV410-420 HLA-A*0101 mut LTEWGSGNRTY NK
MUC1 HLA-A*0201 NLTISDVSV [33] MAGE 1161−169 HLA-A*0101 EADPTGHSY [34]
Muc1 mod HLA-A*0201 KLLLTVLTV [35] EBV BMLF1298-306 HLA A*0301 mut SLSKVILTLK NK
MUC-1 tandem repeat HLA-A*0201 STAPPVHNV [36] EBV BRLF1148-156 HLA-A*0301 mut RVRAYTYSK [37]
MUC1_HUMAN mod HLA-A*0201 SLAPPVHNV [38] EBV EBNA3471-479 HLA-A*0301 RLRAEAQVK [39]
PASD1(1) HLA-A*0201 QLLDGFMITL [40] LMP1_EBV mod. HLA-A*0301 ALFLGIVLK NK
PASD1(2) HLA-A*0201 YLVGNVCIL [40] p53 HLA-A*0301 RVRAMAIYK [41]
PASD1 (Pa14) HLA-A*0201 RLWQELSDI [42] p53321-330 HLA-B*0702 KPLDGEYFTL [43]
PASD1(5) HLA-A*0201 ELSDSLGPV [40] EBV BZLF1 HLA-B*0801 RAKFKQLL [44]
Proteinase 3 HLA-A*0201 VLQELNVTV [45] EBV EBNA3325-333 HLA-B*0801 wt FLRGRAYGL [46]
aOriginal reference for the epitope
b245V mutation of MHC class I as described by [30]
ca random selection of 6,000 peptides, generated as described in reference [17].
HLA: human leukocyte antigen; Mod.: modiﬁed; Mut.: mutated; NK: not known.
doi:10.1371/journal.pone.0140483.t001
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were not included in our analyses and we judged acceptable levels of background by a compari-
son to the patient sample AML006. Every batch of pMHC arrays was tested with the patient
sample AML006, which was HLA-A2 negative and negative for CD8+ T cells binding to all
pMHCs. It was used to control for within batch stickiness of the arrays outside of the pMHC
spots and the sticking of its’ T cells to pMHC spots was always low–no more than 1–2 cells at
any one pMHC spot. In addition fluorochrome alone and random library [17] pMHCs were
used to provide negative controls for CD8 T cells sticking non-specifically to pMHC spots. The
removal of non-CD8 cells from the peripheral blood samples was essential and, as recom-
mended by others [9,10], we always depleted CD11b cells. The pMHC spots were visualised
using low concentrations of AF532, minimised to 2.25% of the total streptavidin used to conju-
gate biotinylated pMHCmonomers, to minimise bleeding of AF532 into the DiD channel
while allowing the user to co-localise pMHC spots and bound T cells using the ProScanArray.
Scanning electron microscopy (SEM)
Further analysis of pMHC arrays by SEM required fixing of the hydrogel slides in 3% glutaral-
dehyde, 4% paraformaldehyde, 0.1M PIPES buffer, pH 7.2, post-fixing in 1% osmium tetroxide,
Fig 1. Diagrammatic representation of the pMHC array. Lipophilically dyed CD8+ T cells (0.8–1.2 x 106 per microarray) were incubated at 37°C in warm
colourless X-VIVO 15 media with the pMHC array. Each pMHC spot contains 1ng of tetramer and each slide can hold up to 1,000 spots of pMHC.
doi:10.1371/journal.pone.0140483.g001
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0.1M PIPES buffer, pH 7.2, dehydration through an ethanol series, critical point dried, mount-
ing on stubs, sputter coated with gold/palladium and subsequent imaging on a Hitachi S800
SEM.
Flow cytometry
FACS analysis was used to demonstrate HLA-A2 positivity on unselected total white blood
cells using the HLA-A2 antibody (clone name: BB7.2) from Serotec. Cells alone and cells incu-
bated with anti-human IgG2a isotype control were also analysed for each sample. The HLA-A2
antibody also detects the 10% of HLA-A2 positive individuals who are HLA-A24 rather than
HLA-A0201 and so a second round of PCR based screening to confirm the full haplotype was
performed either by the Anthony Nolan at the Royal Free Hospital or in-house at the South-
ampton General Hospital. To confirm T-cell populations recognised specific epitopes, we incu-
bated 106 cells with diluted multimers at 4°C for 30min (HLA concentration 5μg/mL) in FACS
buffer containing 50% FCS as described previously [47]. Subsequently cells were incubated
with anti-CD8-Fluorescein isothiocyanate (FITC) antibodies at 4°C for 20min, washed and
analysed on the FACScalibur.
Immunolabelling
White blood cells from the peripheral blood or bone marrow of patients were defrosted and
spotted at 107cells/ml in PBS onto glass slides and allowed to dry for 4-16hrs at room tempera-
ture. Cells were then incubated with hybridoma supernatant from the monoclonal antibody
PASD1-1 which recognises a region common to the PASD1a and PASD1b proteins (clone
2ALCC136) between aa 195–474 or PASD1-2 (clone 2ALCC128) a monoclonal antibody
which is specific for aa 540–773 present only in the longer PASD1b protein [40]. After washing
in PBS, the slides were stained using the Mach-Three detection kit (A. Menarini Diagnostics
(U.K.), Berkshire) following manufacturer’s instructions. Antigen/antibody complexes were
visualized using diaminobenzidine tetrahydrochloride substrate (Sigma).
Results
Optimisation of CD8+ T cell isolation
To optimise the negative isolation of CD8+ T cells we directly compared two of the most popu-
lar techniques using normal donor leukophoresis samples. We found that StemSep beads pro-
vided the highest purity of CD8+ live cells (Fig 2A–method 2) and showed the least dead cells
with the most distinct CD8+/tetramer+ population by flow cytometry (Fig 2B) in at least three
independent tests.
Reproducibility of the pMHC array
To demonstrate the robustness of the pMHC array in our hands we analysed CD8+ T cells
isolated from the peripheral blood of five normal donor samples of which three were
HLA-A0201 positive and had known CMV status (as determined by serology) and Flu-spe-
cific T cells as determined by flow cytometry. By flow cytometry we could reproducibly detect
viral antigen-specific T cells that recognised CMV pp65 and Flu M1 epitopes at frequencies of
less than 0.02% within the total purified CD8+ population. This was achieved using less than
2 x 105 CD8+ T cells per test and collecting80,000 events (exemplified in Fig 3A). In the
same samples we could detect CMV pp65 and Flu M1 specific T cells at the same sensitivities
using the pMHC array (Fig 3B). CD8+ T cells bound to the array were magnified using SEM,
which indicated that CD8+ T cells were bound at the site of the pMHC spot. Furthermore, they
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PLOS ONE | DOI:10.1371/journal.pone.0140483 October 22, 2015 6 / 19
showed a phenotype indicative of activation (Fig 4A & 4B) possibly caused through their inter-
action with a high density of pMHCs on the flat array surface. In addition pits were observed
(Fig 4C) which appeared to be where T cells had been on the gel surface and then detached.
Previous studies [48] have shown that T cells can internalise pMHCs and this may have caused
the release of T cells from the hydrogel surface and an underestimation of T-cell binding to the
pMHC spots.
Fig 2. Direct comparison of epitope specific T cell detection by pMHC tetramers following negative CD8+ isolation by conventional techniques.
CD8+ T cells were isolated from HLA-A*0201+, normal donor buffy coat using commercially available negative isolation kits. This normal donor was CMV
sero-negative, pMHC-CMV pp65 negative and pMHC-Flu M1 positive. (A) 106 cells per test were incubated with 1μg of anti-CD8-FITC antibody, the cells
washed and analysed by flow cytometry using a FACScaliburTM. Method 2 gave the highest number of CD8+ cells (FL1). (B) 106 CD8 T cells isolated from
the same normal donor by Method 1 or 2 were labelled with anti-CD8-FITC (y-axis) and pMHC-(Flu or CMV)-SA-PE (x-axis) and analysed by flow cytometry.
We found that Method 2 StemSep negative isolation of CD8s provided the best separation of pMHC-labelled CD8 T cells, in this case with Flu M1 tetramers.
doi:10.1371/journal.pone.0140483.g002
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Fig 3. Correlation between the detection of specific T cell populations using flow cytometry and pMHC arrays.Negatively isolated CD8+ T cells from
a normal donor who was pMHC-Flu M1 positive and CMV sero-negative were (A) labelled with anti-CD8-FITC (y-axis) and pMHC-(Flu or CMV)-SA-PE (x-
axis) and analysed by flow cytometry. We showed that a minimum 0.7 x 106 CD8+ cells (including controls) could be used to show that the sample had Flu
M1+ specific T cells but not A2/CMV pp65 specific T cells by conventional flow cytometry. CD8-FITC (FL1-H) is shown on the x-axis and pMHC-SA-PE
(FL2-H) staining on the y-axis. (B) 106 CD8+ T cells/ml, from the same normal donor sample, were lipophillically dyed with DiD and incubated for 20 minutes
at 37°C with a custom-made hydrogel slide. Unbound cells were washed away with warm X- VIVO. CD8+ T cells (shown stained red) are visible at the single
cell level bound to the Flu tetramer, which is visualised by the 5% AlexaFluor532 conjugated to streptavidin (shown as a green spot), on the ProScanArray.
Composites show the co-localisation of Flu-specific CD8+ T cells to the Flu M1 tetramer spot. Few if any T cells are bound to the CMV pp65 pMHC spot or the
negative control random pMHC library (also tetramerised with 5% AF532-streptavidin in streptavidin). Limits of detection in both assays were0.1% of the
CD8+ population.
doi:10.1371/journal.pone.0140483.g003
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Identification of simultaneous T cell populations in leukaemia patients
We examined the simultaneous recognition of 40 viral and leukaemia-associated tetramers
(Fig 5A; Table 1) by negatively purified CD8+ T cells from the peripheral blood of 11 leukae-
mia patients. Approximately 45% of Caucasians are HLA-A2 positive [49] and in the cohort of
AML patients studied here, (12/26) 46% were HLA-A2 positive. We did not record ethnicity
for the purposes of this study. It is notable that one patient became HLA-A2 positive post-
transplant (AML022-FU), We found only 4/12 of the AML patients were known to be CMV
sero-positive and three of these were found to be pMHC-HLA-A2/CMV pp65 positive, two
of which were also CMV IE1 positive (Table 2). Only one of the six ALL patient samples had
CD8+ T cells which recognised pMHC-HLA-A2/CMV pp65 and IE1 reflecting an overall lack
of epitope-specific T cells in the ALL and CML patient samples studied.
In contrast, fourteen AML patients recognised one or more LAA epitope, eight of these
AML patient samples had T-cells which recognised the HLA-A2/PASD1 pMHCs, four AML
patients recognised PASD1(2) [50], three AML patients recognised the PASD1 Pa14 [42], with
one patient recognising the PASD1(5) epitope [50].
Patients which recognised one or more antigens also recognised the tyrosinase epitope [24],
while one (AML002) recognised the HLA-A2/MelanA epitope [51,52] and the other
(AML004) the WT1126 epitope (Fig 5B–5E)[30]. It was interesting to note that the patient with
T cells that recognised HLA-A2/WT1126, did not recognise HLA-A2 WT1126 tetramers which
harbour the A245V mutation. This mutation has been shown to enable binding of only the
most avid TCRs, often only binding 10% of patient T cells who have specificity for the unmu-
tated form [30]. Six known HLA-A2 positive patients recognised none of the pMHCs on the
array (Table 2).
We agreed a strict criteria that at least three of six pMHC spots, in both areas of the pMHC
array, had to be bound by epitope specific T cells in order to be scored positive. This was not
the case for ALL003 who had T cells binding to two of six PASD1(2) pMHC spots in two
regions of the array (Fig 5D) as well as MUC1-specific T cells, and AML001 who had PASD1
(5)-specific T cells on two of six pMHC spots in region one and three of six spots in region two
of the pMHC array (Fig 5E). This suggests we may have been underscoring the presence of
Fig 4. CD8+ T cells from leukaemia patients binding to pMHC spots on the pMHC array. (A + B) SEM showing a CD8+ positive T cell bound at the site of
a tetramer spot on the pMHC array; (C) a single pit on the pMHC array suggesting that T cells dig into the hydrogel when binding to pMHCs and subsequently
detach.
doi:10.1371/journal.pone.0140483.g004
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LAA-specific T cells in patient samples but we retained a cut-off for analysis that we knew was
robust from our optimisation phase of analysis using normal donor samples.
We did not know the UPN or HLA type of samples when scoring spots and this “blinded”
process was used to ensure our scoring integrity. However most of the pMHCs used were
HLA-A2 restricted and those that were not were predominantly EBV epitopes used to analyse
Fig 5. Analysis of leukaemia patient samples on the pMHC array. pMHC array (A) printed with 40 tetramers visualised by AlexFluor532 (shown in green,
with bleaching to white at the highest intensity). Each pMHC complex were printed six times consecutively on one or two rows in two different areas of the
hydrogel; Each line contains up to seven pMHC spots shown within the orange box; (B-E) white circles indicate the position of the pMHC spot on the array
while CD8+ lymphocytes visualised by DiD lipophilic staining (shown in red), indicate the presence of epitope specific T cells recognising (B) FLUM1 and
Tyrosinase in AML016; (C) MelanA in AML013FU; (D) MUC1 and PASD1(2) in ALL003 and (E) PASD1(5) in AML001. All epitopes described were
conjugated to MHC Class I (HLA-A2) complex.
doi:10.1371/journal.pone.0140483.g005
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Table 2. Results from pMHC array analysis where there was detectable binding of virus and LAAs-specific pMHCs by “untouched” CD8+ T cells purified
from leukaemia patients.
Patient HLA-A2/
CMV
HLA-A2—pMHC Molecules
ID status CMV
IE1
CMV pp65 Flu
M1
CEAM5 G250 MelanA MUC1950-958 PASD1Pa14 PASD1
(1)
PASD1
(2)
PASD1
(5)
p68
RNA
Helicase
Tyrosinase WT1126-134
AML001 +/-
AML002 +/+ + + + + +
AML003 +a/+
AML004 +/+ + + + + +
AML005 -/+
AML006 - a /+
AML007 -/+
AML008 +/+ + +
AML008b +/+
AML009 -/nk
AML010 A*24/nk +
AML011 - a /nk
AML012 + a /nk +
AML013 +/nk
AML013b +/nk +
AML014 +/nk +
AML015 +/nk
AML015b +/nk
AML016 A*11;30/
nk
+ +
AML016b A*11;30/
nk
AML017 A*01;24/
nk
+
AML017b A*01;24/
nk
AML018 -/nk
AML018b -/nk
AML019 + a /nk
AML020 - a /nk + +
AML021 - a /nk +
AML022 -/nk
AML022b + a /nk +
AML023 +/nk
AML023b +/nk +
AML024 nk/nk
AML025 nk/nk
AML026 nk/nk
ALL001 +/+ + +
ALL002 +/nk
ALL003 +/nk +
ALL004 nk/nk
T-ALL005 +/nk
cALL006 +/nk
cALL007 +/nk
CML001 +/nk
CML002 -/nk
CML003 -/nk
CML004 + a /nk
CML005 -/nk
aAs determined by ﬂow cytometry
bFU: follow-up samples; nk: data not known.
doi:10.1371/journal.pone.0140483.t002
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a single patient at multiple time points who had post-transplant lymphoproliferative disease
and EBV reactivation (Guinn and Orchard, unpublished data).
PASD1 protein expression in patients’ samples
Using immunocytochemistry with two well-characterised PASD1 monoclonal antibodies [40]
we observed PASD1a and PASD1b expression in three AML patient samples: AML004,
AML008 and AML014 (Fig 6) but not in the other 15 patient samples tested (AML001,
AML003, AML006, AML009, AML013, AML015, AML018, AML019, AML021, AML023,
AML026, ALL001, ALL002, CML001 and CML002). In the three patients who had PASD1 pro-
tein expression in their peripheral blood/leukaemia cells this concurred with the presence of
PASD1-specific CD8+ T cells in the periphery as detected by the pMHC array.
Discussion
The use of pMHC technology can provide important information about the effector T-cell
response implicated in tumour immunity. The approach has many benefits including the use
of small numbers of T cells (0.8–1.25 x 106 cells/array), minute amounts of pMHC (1ng/spot;
1/1000th that required for flow cytometry) and the large numbers of spots (up to 1,000) that
Fig 6. PASD1 expression in AML patient samples. Immunolabelling was used to detect PASD1 protein expression in leukaemia patient samples.
Haematoxylin provides the blue background stain to allow differentiation of the cell nucleus from the cytoplasm. The brown precipitate indicates a positive
reaction between secondary antibody and detection reagent, at the antigen site. In this image AML004, AML008 and AML014 immunolabelled cells are
shown, AML015 was one of the samples which did not have demonstrable PASD1 expression. No primary antibody was used as a negative control and actin
was used as a positive control for immunolabelling.
doi:10.1371/journal.pone.0140483.g006
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can be arrayed without haplotype restriction. The pMHC array requires an array printer and
scanner but such equipment is available in most research institutes due to the expansion of
genomic studies over the last decade. The pMHC array can also be used to detect as many spe-
cific T-cell populations as there are pMHCmolecules. Of particular note the pMHC array tech-
nique is inexpensive and can be performed rapidly, making its use as a point of care predictor
of response to therapy a real possibility.
In keeping with previous findings [9], our own optimisation studies demonstrated that the
pMHC array can detect the same specific T-cell populations as the flow cytometer, suggesting
the two techniques share comparable sensitivities. Indeed despite the small amount of pMHC
molecules per spot on the array, and the low frequency of pMHC availability (estimated to be
less than 2% of the total pMHC spotted)[9], the pMHC array can detect T cell populations in
patients which exist at clinically-relevant frequencies (0.1% of the total CD8+ population), with
similar sensitivity to conventional methods of pMHC staining i.e. flow cytometry. Recently
Deviren et al [53] described a pMHC array method in which dimeric MHC-immunoglobulin
complexes (Kb-Ig) were loaded with peptide. These Kb-Ig microarrays, using splenocytes from
a C57BL/6J mouse, were demonstrated to have a lower detection limit than the conventional
pMHC arrays described in these studies. The group also showed that performing the microar-
rays under mild shear flow condition produced more uniform distributions of captured T cells
on individual spots and better spot-to-spot reproducibility across the array. Another variation
of the pMHC array technique, described by Kwong et al [54], called “Nucleic Acid Cell Sorting”
(NACS) involves the site-specific immobilization of pMHC tetramers by single-stranded DNA
oligomers on glass slides. The authors state that the method outperforms spotted arrays in
their hands when assessed on the key criteria of repeatability and homogeneity but we found
neither aspect compromised in our hands due, we believe, to our aggressive washing technique
and use of negatively isolated “untouched” CD8+ T cells. However both the Kb-Ig and NACS
arrays may reduce T-cell loss, through the prevention of pMHCmolecules uptake by bound T
cells at room temperature [48]. Such uptake may explain the pitting we observed in the hydro-
gel when assessing pMHC spots using SEM (Fig 4C) as our arrays were incubated at 37°C for
20min prior to scanning.
The frequency of T cells adhering to a pMHC spot is believed to depend on a number of fac-
tors including the abundance of the T cells expressing the appropriate TCR, levels of TCR
expression, and their affinity for the pMHC complex [9]. Development of a bound CD8+ T cell
quantitation system is still required, although single cells were visible on the array at high mag-
nification. In addition we used SEM to examine the features of T cells bound to the pMHC
array. This technology did not lend itself to determining which pMHC spots had T cells bound
but did demonstrate the morphology/activated nature of T cells bound to pMHC spots (Fig 4A
and 4B). When we examined T cells following array scanning under the light microscope we
found that almost all bound T cells appeared dead with a granulated nucleus and blebbed sur-
face typical of cells undergoing apoptosis (data not shown). To minimise this we performed all
steps and used solutions at 4°C, but this had little if any measurable impact on the number of T
cells bound to the pMHC spots to the array, T cell survival or the frequency of array gel pitting.
Activation induced cell death may have been caused by the high density of pMHC printed on
the flat surface of the hydrogel, toxicity from the chemicals in the polyacrylamide gels or high
temperatures and drying in the scanner. This death occurred rapidly and was seen within 25
minutes of first spotting T cells onto the pMHC arrays.
En mass production of all pMHCs for printing on the pMHC array is the most expensive
and time consuming part of this technology although this may be circumvented through the
use of UV-induced peptide exchange technology [55,56]. There is some limitation to the tech-
nology as it depends on the affinity of the new ligand for the MHCmolecule [56,57] but studies
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have shown that the pMHC complex formed after UV-induced ligand exchange is identical to
that obtained by classical refolding [58].
We chose to store purified negatively isolated “untouched” CD8+ T cells from patients in
liquid nitrogen and only print pMHCs onto hydrogel slides in the week prior to analysis of
groups of patient samples. Printing was performed in batches of up to 50 slides, although up to
200 can be printed in a day using the Genetix printer. Biotinylated pMHCmonomers were
stored at -80°C and tetramerised in the week prior to printing. One of the issues considered
was the deterioration of some pMHCs after printing although Soen et al [9] suggested that the
life of pMHCs are extended from one month at 4°C to six months at 4°C in hydrogel. To deter-
mine when the pMHCs had deteriorated we printed single pMHC arrays with pMHCs tetra-
merised from independent aliquots of monomers two weeks apart so that the time-point of
deterioration of the pMHC would be obvious. We found that some pMHCs started to deterio-
rate in the hydrogel after six weeks, as seen by decreased levels of AF532 fluorochrome in the
gel at the site of pMHC spotting and decreased T cell binding by samples. Hence we analysed
the negatively purified CD8+ T cells on arrays within one month of printing.
PASD1 is one of the most frequently expressed tumour antigens in AML [59] and PASD1
epitopes have been found to be recognised by T cells from AML patients ([42] and this study).
However this is the first study in which PASD1-specific T cell populations have been examined
in direct comparison to other LAA-specific T cells in AML and PASD1 epitopes appears to be
the most frequently recognised. However this may reflect the predominance of PASD1 pMHCs
on the array which will be redressed in future studies.
We examined the protein expression of PASD1a and PASD1b in 18 of the patient samples
in our study. Only three samples expressed both PASD1a and PASD1b protein of the eight
samples which had PASD1-specific pMHCs. The lack of expression in other patient samples,
despite the presence of PASD1-specific T cells in the periphery suggests that these samples had
not attracted PASD1-specific T cells from the periphery to the tumour or the T cells had
already killed the PASD1 expressing tumour cells. Of note was the predominance of PASD1-
specific T-cell responses in 8 of 26 AML patients, perhaps reflecting the presence of four
HLA-A2 restricted pMHC-PASD1 on the array, rather than the single pMHC-epitopes
detecting most other tumour antigens. However PASD1 has been one of the most frequently
expressed CTA in myeloid leukaemia [59] while WT1 has been found to be one of the most fre-
quently expressed LAAs [60].
We had hoped that the pMHC array would help us prioritise PASD1 epitopes for vaccine
use in clinical trials but a larger cohort of AML patients would be required. Four AML patients
had T cells that recognised PASD1(2) [50] however two of these four (AML017 and AML020)
were HLA-A2 negative. In addition three AML patients who were not HLA-A0201 positive
(AML016, AML017 and AML020) had LAA specific T cells which recognised PASD1(5)-
HLA-A0201 presented epitopes. This was unexpected but may reflect the promiscuity of the
TCR which only recognises one or two amino acids in an epitope and as such one TCR can rec-
ognize numerous pMHC, in fact each T-cell is believed to be responsive to at least four distinct
determinants within three different MHCs [61,62].
It was notable that few of the pMHCs available on the array were recognised by CML or
ALL patients although numbers of patient samples from these groups were extremely small
(n = 5 and n = 7, respectively). The pMHC array predominantly harboured HLA-A2 restricted
pMHCs, representing those most frequently requested by collaborators of Professor HG Ram-
mensee, and all had been functionally verified through local use prior to use on the pMHC
array.
To optimise the targeting of AML patient samples, when diseased cells are heterogeneous in
their expression of LAAs, the targeting of multiple antigens and/or multiple epitopes therein
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may be more effective at removing residual disease and escape variants [63]. Synthetic long
overlapping peptides have been shown to be very effective for this mode of immunotherapy
[64] and can overcome some of the short-term responses seen with single peptide vaccines
[65]. The fact that four patients who had PASD1 specific T cell populations also had PASD1
expression in their leukaemia cells suggests the LAA specific-T cells are present in the periph-
ery but are not effectively killing PASD1+ tumour cells.
We [66] and others [67] have previously shown that the expression of above median levels
of LAAs, such as SSX2IP alone, or in combination with SURVIVIN and receptor for hyaluro-
nan-mediated motility (RHAMM), in presentation AML patients who lack cytogenetic rear-
rangements, can predict survival following conventional treatment (chemotherapy). This is
believed to be due to the expression of distinct LAAs on leukemic blasts leading to the eradica-
tion of residual disease after intensive chemotherapy [67]. The effective clearance of dead and
dying leukaemia cells by phagocytes post-treatment and the presentation of antigens in the
presence of “danger signals” such as inflammation may stimulate effective anti-leukaemia T-
cell responses. Indeed the reduced survival observed in older patients following conventional
treatment may in part be explained by the lower LAA expression observed in these patients
[67] who often respond poorly to chemotherapy. Other groups have shown a correlation
between tumour infiltrating T cells and good survival in patients with oropharyngeal cancer
[68]. We found no correlation between HLA-A0201 positive leukaemia patients with T cells
which recognised LAA-specific epitopes and better survival following standard therapy, than
survival in those that did not have LAA-specific T cells, in part reflecting the small numbers of
HLA-A2 patients analysed to date.
We have shown that our pMHC array can be used to detect CD8+ T cell populations which
exist in leukaemia patients at disease presentation without the need for any ex vivo expansion.
This technology may be used to track the waxing and waning of specific-T cell populations
during conventional and immunotherapy treatments. In addition the simultaneous examina-
tion of LAA-specific T-cell populations will allow the examination of epitope spreading follow-
ing conventional and immunotherapy treatments as well as aiding immunotherapy (timing,
dose response) and personalized therapy development in the future.
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